Comparative Pharmacology
Head-to-head clinical analysis: ENHERTU versus OSIMERTINIB MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENHERTU versus OSIMERTINIB MESYLATE.
ENHERTU vs OSIMERTINIB MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-HER2 IgG1, and the small molecule DXd is a topoisomerase I inhibitor. Upon binding to HER2 on tumor cells, the ADC undergoes internalization and intracellular cleavage, releasing DXd which causes DNA damage and apoptotic cell death.
Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively inhibits EGFR exon 19 deletion and L858R substitution mutations, as well as T790M resistance mutations, with less activity against wild-type EGFR.
5.4 mg/kg intravenously every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
80 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 5.5 days (range 4.5–7.5 days) for the antibody-drug conjugate, supporting every-3-week dosing.
Terminal elimination half-life is approximately 48 hours (range 36-60 h) based on population pharmacokinetic analysis, supporting once-daily dosing.
Primarily biliary/fecal excretion (approximately 95% as unchanged drug); renal excretion is negligible (<1%).
Osimertinib is eliminated primarily via feces (67.8%, with 1.2% as unchanged drug) and urine (13.8%, with 0.8% as unchanged drug). The remainder is recovered as metabolites.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent